Teclistamab salvage therapy for multiple myeloma relapse after allogeneic hemopoietic stem cell transplant: A case report-Reference-Cited by-同舟云学术

Teclistamab salvage therapy for multiple myeloma relapse after allogeneic hemopoietic stem cell transplant: A case report

Published:2023-11-30 Issue:1 Volume:99 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Zaja Francesco¹²^ORCID,Lucchini Elisa²,Poiani Monica²,Sbisà Eugenio²,Mohamed Sara²,De Bellis Eleonora²,Caizzi Manuela²,Palmieri Clara³,Loiacono Stefano³,Granzotto Marilena⁴,Sirianni Francesca⁴,De Sabbata Giovanni²

Affiliation:

1. Dipartimento di Scienze Mediche, Chirurgiche e della Salute Università degli Studi di Trieste Trieste Italy

2. UCO Ematologia Azienda Sanitaria Universitaria Giuliano Isontina Trieste Italy

3. SC Farmacia Ospedaliera e Territoriale Azienda Sanitaria Universitaria Giuliano Isontina Trieste Italy

4. Laboratorio Unico Azienda Sanitaria Universitaria Giuliano Isontina Trieste Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27159

Reference6 articles.

1. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

2. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

3. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

4. Teclistamab in Relapsed or Refractory Multiple Myeloma

5. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Teclistamab/thalidomide;Reactions Weekly;2024-05-25

2. Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient;Current Oncology;2024-05-09